Coats disease is a sporadic, chronic retinal vascular disorder with telangiectatic and aneurysmal retinal vessels, with retinal exudation and retinal detachment in severe cases. Various treatment modalities have been used, including laser therapy, cryotherapy, anti-vascular endothelial growth factor (VEGF) therapy, and surgery. Anti-VEGF therapy seems to be effective in reducing exudative changes and is often combined with other treatment modalities. For severe cases with exudative retinal detachment, external drainage of subretinal fluid with or without vitrectomy is commonly performed, combined with laser therapy and/or cryotherapy. Relatively good anatomical outcomes have been reported; however, postoperative functional results, particularly in young patients and/or severe cases, seem to be limited.
MANAGEMENT
The current treatment modalities for Coats disease include laser therapy, cryotherapy, anti-vascular endothelial growth factor (VEGF) therapy, and surgery for repair of retinal detachment. The techniques for surgery are external subretinal fluid drainage with or without vitrectomy, which can be combined with laser therapy, cryotherapy, or anti-VEGF therapy. Currently, no consensus exists regarding the choice of treatment to be performed, and decisions are usually made based on surgeons' preferences depending on the stage 3 ( Table 1 ) and severity of the disease.
Laser Therapy
Laser therapy for Coats disease was first described by Meyer-Schwickerath et al 4 in the 1960s. Since then, this has become standard therapy for Coats disease, especially in the early stages. 5, 6 The basic concept of laser therapy is to stop leakage from abnormal and aneurysmal vessels via direct coagulation. Therefore, laser ablation of abnormal vessels needs to be performed. A conventional green or yellow laser with a relatively long duration (0.1-0.5 seconds) is preferred to produce effective closure of the vessels. In addition, laser ablation needs to be performed on the surrounding nonperfused areas, which may stimulate production of VEGF. This therapy is less effective if the abnormal vessels are located on the detached retina.
Cryotherapy
The basic rationale for the use of cryotherapy in Coats disease is the same as that of laser therapy. At early stages, laser therapy is preferred because it is less invasive than cryotherapy. Cryotherapy is more frequently used in severe cases because it is more effective in producing burns even in the detached retina. Cryotherapy may be performed 2 or 3 times within the same session under indirect ophthalmoscopy (double or triple freeze-thaw technique). 7, 8 Anti-VEGF Therapy Evidence has been accumulating that VEGF is increased in the vitreous and in the subretinal fluid in eyes with Coats disease. 9, 10 Previously, VEGF was known as vascular permeable factor because it induces vascular leakage and edema in adjacent tissues. 11 Therefore, the use of anti-VEGF agents has been attempted to improve disease conditions in Coats disease, and the efficacy either in monotherapy or in combination with triamcinolone or ablation therapy has been reported in case series with relatively small numbers of patients. 9, 10, [12] [13] [14] [15] Anti-VEGF therapy seems to be effective in improving intra-or subretinal exudative changes (Figs. 1, 2) . However, its efficacy may be transient and repeated treatment may be necessary, as in cases of diabetic macular edema or macular edema associated with vein occlusion, necessitating combination with ablation therapy. A possible limitation of anti-VEGF therapy is that it may induce vitreoretinal fibrosis and tractional retinal detachment. 15, 16 However, it is unclear if such changes are solely the effects of anti-VEGF therapy because similar phenomena are also seen after ablation therapy alone. Further studies are necessary to establish the efficacy and safety of anti-VEGF therapy in Coats disease.
Surgical Treatment
In eyes with extensive exudative retinal detachment, ablation therapy and/or anti-VEGF therapy may not be effective enough to suppress disease activity and stabilize disease conditions. Moreover, laser therapy is sometimes ineffective in creating burns on the detached retina. Direct coagulation of abnormal vessels on the detached retina via laser therapy or cryotherapy may be possible, but improvement in disease status is likely to be limited. Direct coagulation is sometimes difficult in eyes with total retinal detachment because abnormal vessels located in the peripheral retina are often invisible in such eyes. Anti-VEGF therapy has been reported to be effective even in such eyes. 12, 14 However, in most cases with extensive retinal detachment, anti-VEGF therapy alone may not be sufficient to improve conditions.
The most common surgical method in such cases is external drainage of subretinal fluid, which has been performed for several decades 3, 5, 8, 10, [17] [18] [19] [20] [21] [22] (Fig. 3) . Although some surgeons use internal drainage of the subretinal fluid, this technique is apparently more invasive and is used primarily in less severe cases. 23 It is reported that the subretinal fluid in Coats disease patients contains high concentrations of VEGF. 10 Anti-VEGF agents, especially bevacizumab with a large molecular weight, seem to infiltrate poorly into the subretinal space. Therefore, drainage of the subretinal fluid should theoretically be effective and immediate improvement (ie, retinal reattachment) is expected to be achieved. To normalize intraocular pressure, BSS Plus may be injected either into the anterior chamber or into the vitreous space through the pars plana. Injection into the anterior chamber is safer because it has no possibility of retinal damage. After retinal reattachment, the choice of treatment options differs based on the surgeon's preference. Some surgeons prefer transpupillary laser therapy and/or cryotherapy without vitrectomy. 8, 17 Other surgeons prefer vitrectomy and endophotocoagulation. [20] [21] [22] [23] Endophotocoagulation can be performed via a nonvitrectomy approach. 19 Anti-VEGF therapy may be combined with any of the above techniques. 17 Each technique has its merits and demerits. Vitrectomy is beneficial in removing vitreous that contains VEGF, although it can be reduced using anti-VEGF therapy. Cases with epiretinal membranes and/or vitreous traction, which often exist in the peripheral retina, especially after ablation therapy, can be treated using vitrectomy.
Disadvantages of vitrectomy include higher risk of complications and technical difficulty. The most serious complication is probably the creation of an iatrogenic retinal break. If such a break is created on a retina without surrounding exudate in an eye with minimal disease, the retinal break can be sealed and the retina reattached without much difficulty. However, if it is created on a retina with large amounts of surrounding exudates in an eye with high disease burden, retinal reattachment can be very challenging. This is because laser burn cannot be created on a retina with underlying exudate, and the risk of developing proliferative vitreoretinopathy may be relatively high in an eye with high concentrations of VEGF. Surgical results with or without vitrectomy are relatively successful, with success rates ranging from 50% to 100%, as summarized in Table 2 . However, repeated treatments are common in the management of Coats disease. In general, younger patients tend to have more severe disease and a greater extent of retinal detachment, as pointed out by Shields.
2 Studies with younger patients tend to generate worse results.
CONCLUSIONS
Laser therapy and/or cryotherapy on abnormal, leaking vessels are commonly performed and seem to be effective in Coats disease of stage 2 to stage 3A. However, for eyes with more extensive exudative retinal detachment (stage 3A or higher), external drainage of the subretinal fluid with or without vitrectomy is 9.5 (≥5) y preferred, and relatively successful surgical outcomes have been reported. Overall, less invasive methods are preferable, especially in eyes with severe disease that may be at risk for developing proliferative vitreoretinopathy.
